section name header

Pronunciation

doe-FET-il-ide

Classifications

Therapeutic Classification: antiarrhythmics (class III)

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: Well absorbed (>90%) following oral administration.

Distribution: Widely distributed to tissues.

Metabolism/Excretion: Primarily metabolized in the liver via the CYP3A4 isoenzyme; 80% excreted by kidneys via cationic renal secretion, mostly as unchanged drug; 20% excreted as inactive metabolites.

Half-life: 10 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POwithin hrs2–3 hr12–24 hr

†Steady state levels are achieved after 2–3 days.

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: chest pain, QT interval prolongation, TORSADES DE POINTES.

Neuro: dizziness, headache.

Interactions

Drug-Drug:

Drug-Food:

Route/Dosage

Dosing should be adjusted according to renal function and assessment of QT interval

Renal Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Tikosyn